CIMA Sciences, In Partnership with Luxor Scientific Launches Revolutionary Liver Disease Test

Recent advancements signify a new era in liver disease diagnosis and treatment.

~ Recent advancements signify a new era in liver disease diagnosis and treatment. ~

GREENVILLE, SC May 15, 2024 – Luxor Scientific and CIMA Sciences join forces for the US launch of OWLiver®, an exclusive non-invasive blood test able to detect all dangerous stages of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH). The OWLiver® metabolic assay meets the urgent need for a non-invasive test for identification of individuals who have “at-risk” MASH and are at high risk for progressing to end-stage liver disease. This collaboration coincides with the FDA’s March 2024 approval of the first and only medication for MASH treatment, marking a transformative step forward in enhancing liver disease testing and management.

Luxor Scientific is the only laboratory offering CIMA Sciences’ OWLiver® testing in the US, which utilizes the MASEF® (Metabolomics-Advanced Steatohepatitis Fibrosis) score.1 With advanced metabolomics technology, this test holds the potential to transform approaches in understanding and treating metabolic dysfunction associated liver conditions.

“As we continue to see a rise in metabolic syndrome in the US, MASLD is becoming more and more prominent,” stated Dr. Marion Snyder Luxor Scientific. “For years, physicians have had to rely on invasive liver biopsy procedures and costly imaging studies. OWLiver® can identify MASLD in its early stages, giving patients the chance to stop and reverse the disease and live a healthier lifestyle.”

MASLD, previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), is the most common cause of chronic liver disease, impacting over 30% of adults in the US, and is expected to increase in the coming years with the steady rise of obesity, diabetes, and metabolic syndrome. As many as 20% of type 2 diabetic individuals with MASLD will develop MASH. Studies show that 15-20% of patients with MASH can progress to liver disease and ultimately liver failure. Early identification of “at-risk” MASH is a priority, as these patients are at increased risk for disease progression and may benefit from developed therapies to prevent the disease and further liver damage and related complications.

“The availability of this test is incredibly significant for patients at this time,” expressed Alejo Llopart-Mascaro, CIMA Sciences. “We take pride in our collaboration with Luxor Scientific to address the growing issue of metabolic associated liver disease. This partnership enables healthcare providers to diagnose and subsequently offer effective treatments that are now readily available to their patients.”

About CIMA Sciences, LLC

Strategically bringing proprietary technology to the US, CIMA Sciences is a biological company which primary focus is on developing and providing the scientific community and the US population with cutting-edge, non-invasive diagnostic technologies for high-prevalence diseases, with a specific emphasis on liver and cardiovascular risk. CIMA recognizes the critical need for accurate and early detection of diseases and aims to revolutionize the diagnostic landscape and empower healthcare professionals with groundbreaking, accurate, non-invasive and accessible tools to identify and manage these conditions effectively. CIMA actively collaborates with key stakeholders in the scientific and medical communities to ensure the effective deployment of its solutions and their integration into existing healthcare systems. For more information about CIMA Sciences, please visit

About Luxor Scientific

Luxor Scientific was founded with the mission of providing better information faster. As a full-service privately-held CAP-accredited medical and research laboratory, Luxor offers a robust menu of clinical and anatomical testing services. Today, Luxor Scientific is one of the fastest-growing companies in the southeast, specializing in cutting-edge diagnostic testing solutions in the areas of metabolomics, genomics, toxicology and histology. Luxor’s industry-leading turnaround times and state-of-the-art equipment and diagnostic solutions, allows Luxor to provide personalized service, accurate testing, and innovative functional reporting. For more information about Luxor Scientific and our full test offering, please visit

[1] The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2024 Jan 1;79(1):135-148.doi: 10.109724

Media Contact:

Kristina Loughrey